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Abstract
Approximately 20% of patients with acute Q fever develop Q fever fatigue syndrome (QFS), a debilitating fatigue syndrome.
This study further investigates the role ofC. burnetii-specific IFNγ, but also IL-2, CXCL9, CXCL10, and CXLC11 production in
QFS patients. C. burnetii-specific IFNy, IL-2, CXCL9, CXCL10, and CXCL11 production were tested in ex vivo stimulated
whole blood of QFS patients who recovered from their complaints (n = 8), QFS patients with persisting complaints (n = 27), and
asymptomatic Q fever seropositive controls (n = 10). With the exclusion of one outlier, stimulation with C. burnetii revealed
significantly higher IFNy and CXCL10 production in QFS patients with persisting complaints (medians 288.0 and 176.0 pg/mL,
respectively) than in QFS patients who recovered from their complaints (medians 93.0 and 85.5 pg/mL, respectively) (p = 0.041
and 0.045, respectively). No significant differences between groups were found for C. burnetii-specific IL-2, CXCL9, and
CXCL11 production. These findings point towards a difference in cell-mediated immunity in QFS patients with persisting
complaints compared to those who recovered from their complaints. Such a difference may aid to eventually diagnose QFS
more objectively and might serve as an indicator of its underlying etiology.
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Introduction
Q fever is a zoonotic disease caused by the Gram-negative
intracellular bacterium Coxiella burnetii that occurs world-
wide [1]. Human primary infection is thought to remain
asymptomatic in approximately 60% of cases with the other
40% resulting in symptomatic infection. Symptomatic
primary infection with C. burnetii is called acute Q fever
and usually presents as a self-limiting flu-like illness, pneu-
monia or hepatitis [1]. Approximately 20% of acute Q fever
patients develop a prolonged state of debilitating post-
infectious fatigue, called Q fever fatigue syndrome (QFS)
[2–4]. Contrary to chronic Q fever, a persistent and life-
threatening infection of pre-existing vascular and/or valvular
lesions or prostheses [5], no signs of active infection are found
in QFS. During the Q fever outbreak in the Netherlands be-
tween 2007 and 2011, over 4000 acute Q fever cases were
notified, and it is estimated that at least 32,200 people were
infected [6]. Ever since, hundreds of patients have been diag-
nosed with QFS [6, 7].
Diagnosing QFS is challenging and requires careful clini-
cal evaluation and exclusion of chronic Q fever and otherwise
causative somatic and psychiatric diseases [Dutch guideline
on Q fever fatigue syndrome, National Institute for Public
Health and the Environment]. Testing for C. burnetii-specific
antibodies has an important role in diagnosing QFS. Not only
for excluding chronic Q fever but also to confirm a past Q
fever infection. Unfortunately, C. burnetii-specific antibody
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titers are not related to perceived complaints during QFS and
are therefore unable to differentiate QFS from a past Q fever
infection. A recent study by our group, however, showed al-
tered cell-mediated immunity in QFS patients that might help
diagnose them in a more objective manner [8]. The
C. burnetii-specific whole-blood interferon-γ (IFNγ) produc-
tion assay showed promising results in differentiating QFS
patients from Q fever seropositive controls and further imple-
mentation of an IFNγ/interleukin-2 (IL-2) ratio helped differ-
entiate QFS patients from chronic Q fever patients [8].
Furthermore, a recent study has shown a promising role for
chemokines CXCL9, CXCL10, and CXCL11 as potential
new biomarkers for persistent infection with C. burnetii, i.e.
chronic Q fever [9].
This study further investigates the role of the C. burnetii-
specific whole-blood IFNγ and IL-2 production assay and
adds CXCL9, CXCL10, and CXCL11, as possible biomarkers
for perceived complaints in QFS. We start by comparing
antigen-specific whole-blood IFNγ and IL-2 production in
QFS patients who have recovered from their complaints,
QFS patients who have persisting complaints, and asymptom-
atic Q fever seropositive controls. Finally, by adding antigen-
specific whole-blood CXCL9, CXCL10, and CXCL11 pro-
duction to this assay, we examine whether we can enhance
biologic differentiation between these groups.
Materials and methods
Study population
The study population consisted of QFS patients (n = 35)
and a group of asymptomatic Q fever seropositive con-
trols (n = 10). All QFS patients were diagnosed at the
Radboud Expertise Center for Q fever, Nijmegen, the
Netherlands, after a uniform work-up according to the
Dutch guideline on QFS. At diagnosis, all QFS patients
met the following criteria: (i) fatigue lasting ≥ 6 months;
(ii) sudden onset of severe fatigue, defined as a score ≥ 35
on the subscale fatigue severity of the Checklist
Individual Strength (CIS), or significant increase in fa-
tigue related to a symptomatic acute Q fever infection;
(iii) chronic Q fever and other causes of fatigue, somatic
or psychiatric, were excluded; and (iv) fatigue resulted in
significant functional impairment, defined as a total
score ≥ 450 on the Sickness Impact Profile (SIP). All pa-
tients who were recruited for this study primarily partici-
pated in the Qure study [10]. In the Qure study, 154 men
and non-lactating women with QFS aged ≥ 18 years were
equally randomized with a 1:2 ratio between two treat-
ment groups: cognitive behavioral therapy (CBT) (n =
50) and medication (n = 104). In the medication group, a
second double-blinded randomization was performed
between doxycycline and placebo treatment [10]. One
year after completion of the Qure study, patients who
were allocated to the CBT and placebo treatment groups
were asked to donate blood (5 mL) at a local health center
and fill-out CIS questionnaires for this study. A cut-off
score of 35 on the CIS subscale Fatigue Severity was used
to differentiate recovered QFS patients (CIS subscale
Fatigue Severity score < 35) from QFS patients with per-
sistent complaints (CIS subscale Fatigue Severity score ≥
35). Asymptomatic Q fever seropositive controls who pre-
viously participated in the ‘Q-Herpen-II’ study were
contacted by mail and asked to donate blood (5 mL) at
a local health center [11].
In vitro whole blood stimulation
The cellular immune response to C. burnetii was mea-
sured using a commercially available whole blood Q fever
IFNγ release assay, Q-detect (Innatoss, Oss, the
Netherlands), according to the instructions of the
manufacturer.
Q-detect utilizes a heat-killed C. burnetii antigen pre-
pared at Wageningen Bioveterinary Research (WBR) in
Lelystad (the Netherlands). The antigen is based on a
proprietary strain, C. burnetii 2009-02629, which was iso-
lated at the WBR from a goat placenta during the Dutch Q
fever outbreak in 2009. The strain was cultured in axenic
medium. Culture methods were based on Omsland et al.
[12]; bacteria were collected by centrifugation, washed in
PBS, and heat-killed for 30 min at 99 °C. The antigen
preparation was calibrated against a similar preparation
of the reference Nine Mile strain [13].
For Q-detect, whole blood is collected in lithium heparin-
coated tubes (Vacutainer, Becton Dickinson). Within 12 h af-
ter blood collection, 180 μL whole blood is mixed with 20 μL
heat-killed C. burnetii in a polypropylene 96-well plate
(Greiner). As respectively negative and positive controls,
RPMI medium (ThermoScientific) and phytohemagglutinin
(ThermoScientific, 1.5% final concentration) were used.
Plates were sealed and incubated for 22–24 h at 37 °C, after
which plates were kept at 2–8 °C. After incubation, superna-
tants were collected and stored at − 20 °C until cytokine
measurement.
Cytokine measurements
IFNγ production was measured by enzyme-linked immu-
nosorbent assay (ELISA; Pelikine compact, Sanquin,
Amsterdam, the Netherlands), according to the manufac-
turer ’s instructions. IL-2, CXCL9, CXCL10, and
CXCL11 were measured using a multiplex beads assay
(Bio-Rad, CA, USA) according to the manufacturer’s
instructions.
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Ethical statement
All participants provided written informed consent and the
study was approved by the Medical Ethical Review
Committee of the Arnhem-Nijmegen region.
Statistical analysis
Data were analyzed using Graphpad Prism (Graphpad
Software Inc., version 5.03) and SPSS (Version 22.0, SPSS,
Inc). Either the Mann-Whitney U test or Kruskal-Wallis test
were used as non-parametric tests to determine differences
between groups. The correlation between patient characteris-
tics and IFNγ, IL-2, CXCL9, CXCL10, and CXCL11 produc-
tion was determined with the non-parametric Spearman’s rank
correlation coefficient. Statistical significance was attained if
p < 0.05.
Results
Patients and controls
At the time of blood collection, QFS patients had either recov-
ered from their complaints (n = 8) or had persisting complaints
(n = 27), depending on their score on the CIS subscale Fatigue
Severity. Asymptomatic Q fever seropositive controls (n = 10)
had IgG phase I or II titers of ≥ 1:64 in 2014 but did not fulfill
the Dutch Consensus Guidelines for chronic Q fever [14]. At
the time of blood collection, all asymptomatic Q fever sero-
positive controls scored < 35 on the CIS subscale Fatigue
Severity. The mean age of QFS patients with persisting com-
plaints was 50.7 years (standard deviation (SD) 11.9), which
did not significantly differ from 52.8 (SD 12.8) and 53.4 (SD
10.6) for QFS patients who recovered from their complaints
and asymptomatic Q fever seropositive controls (p = 0.794),
respectively. Gender distribution also did not differ signifi-
cantly between groups (p = 0.841) (Table 1).
IFNγ and IL-2 production
Stimulation with C. burnetii for 24 h yielded a median IFNγ
production of 288 pg/mL for QFS patients with persisting
complaints, 107 pg/mL for QFS patients who recovered from
their complaints, and 267 pg/mL for asymptomatic Q fever
seropositive controls, but showed no significant difference
between groups. No significant difference was observed in
median IL-2 production between QFS patients with persisting
complaints (median 147 pg/mL), QFS patients who recovered
from their complaints (median 114 pg/mL), and asymptomatic
Q fever seropositive controls (median 289 pg/mL).
Converting IFNγ and IL-2 production to an IFNγ/IL-2 ratio
for each subject also did not significantly differentiate be-
tween groups (Table 2 and Fig. 1a–c).
As can be seen in Fig. 1a, there is one patient with an
C. burnetii-specific IFNγ production of 533 pg/mL who is
clearly an outlier and continues to behave like this in the other
measurements (Fig. 1b–f). Retesting these results produced
similar concentrations. Clinically, the patient did not differ in
any way from the others within the group of recovered QFS
patients.
With the exclusion of this patients, a significantly higher
IFNy production was found in QFS patients with persistent
complaints (median 288 pg/mL) compared to QFS patients
who recovered from their complaints (median 93 pg/mL)
(p = 0.041). No significant difference between groups was
found for C. burnetii-specific IL-2 production or IFNγ/IL-2
ratio.
Table 1 Baseline characteristics
of patients with Q fever fatigue
syndrome (QFS) and
asymptomatic Q fever
seropositive controls
QFS-recovered
(n = 8)
QFS-persisting
complaints (n = 27)
Q fever seropositive
controls (n = 10)
Female gender (%) 5 (62.5) 16 (59.3) 5 (50.0)
Mean age, years (±SD) 52.8 (± 12.8) 50.7 (11.9) 53.4 (10.6)
Mean CIS subscale Fatigue
Severity (±SD)
22.0 (14.3–29.0) 49.0 (43.0–53.0) 17.5 (15.0–35.0)
Median symptom duration,
months (IQR)a
29.5 (23.8–52.0) 92.0 (84.0–104.0) –
Placebo (%)b 4 (50.0)c 14 (51.9)d –
CBT (%)b 4 (50.0) 13 (48.1) –
QFSQ fever fatigue syndrome, SD standard deviation,CISChecklist Individual Strength, IQR interquartile range,
CBT cognitive behavioral therapy
a Symptom duration: time onset of symptoms until blood sampling
bAllocated treatment during the Qure study
cOne out of four followed additional CBT treatment
d Two out of 14 followed additional CBT treatment
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CXCL9, CXCL10, and CXCL 11 production
Stimulation with C. burnetii for 24 h yielded no significant
difference in median CXCL10 production between QFS pa-
tients with persisting complaints and QFS patients who recov-
ered from their complaints (medians 176 and 97 pg/mL, respec-
tively). No significant differences were found comparing
CXCL9 and CXCL11 production between QFS patients with
persisting complaints (medians 803 and 18 pg/mL, respective-
ly) and QFS patients who recovered from their complaints (me-
dians 436 and 19 pg/mL, respectively) (Table 2 and Fig. 1d–f).
When excluding the same patient as for the analysis above,
stimulation with C. burnetii for 24 h revealed significantly
higher CXCL10 production in QFS patients with persisting
complaints (median 176 pg/mL) than in QFS patients who
recovered from their complaints (median 86 pg/mL) (p =
0.045). No significant difference between groups was found
for C. burnetii-specific CXCL9 and CXCL11 production.
Correlations between patient characteristics
and cytokine and chemokine measurements
Correlations between several patient characteristics and cyto-
kine and chemokine measurements were investigated. No cor-
relation was found between IFNγ, IL-2, CXCL9, CXCL10, or
CXCL11 production and level of fatigue or symptom dura-
tion, regardless of the one outlier.
Discussion
In this study, we investigated the relation of antigen-specific
biomarkers IFNγ, IL-2, CXCL9, CXCL10, and CXCL11 to
perceived complaints in QFS. Except for one outlier, both
antigen-specific IFNγ (p = 0.041) and CXCL10 (p = 0.045)
production were higher in QFS patients with persisting com-
plaints, than in those who recovered from their complaints. No
significant difference in antigen-specific IFNγ and IL-2 pro-
duction, and IFNγ/IL-2 ratio, was found between QFS pa-
tients and asymptomatic Q fever seropositive controls, or in
antigen-specific IL-2, CXCL9, and CXCL11 production be-
tween QFS patients with persisting complaints and QFS pa-
tients who recovered from their complaints. These results
point towards an altered cell-mediated immunity between
these groups and indicate that both antigen-specific IFNγ
and CXCL10 production could serve as potential biomarkers
for perceived complaints in QFS.
Antigen-specific production of IFNγ and IL-2 mainly orig-
inates from sensitized effector and memory T cells [15],
whereas CXCL9, CXCL10, and CXCL11 are chemokines,
inducible by IFNγ, produced by various cell types, e.g., lym-
phocytes and macrophages, but also endothelial cells and fi-
broblasts [16]. Previously, our group showed that antigen-
specific IFNγ production was significantly higher in QFS
patients (n = 28; 319.4 pg/mL) than in Q fever seropositive
controls (n = 135; 120 pg/mL) [8]. It was also shown that
antigen-specific IFNγ production is a useful tool for diagnos-
ing a previous Q fever infection [13], and adding antigen-
specific IL-2 production helped discriminate chronic Q fever
patients from Q fever seropositive controls and QFS patients
[8, 17]. In this study, antigen-specific IFNγ production was
not significantly higher in QFS patients than in asymptomatic
Q fever seropositive controls. We did show that it may be
possible to discriminate QFS patients with persistent com-
plaints from recovered QFS patients, with the latter showing
lower antigen-specific IFNγ production than the former, even
Table 2 Median C. burnetii-
specific production of IFNγ and
IL-2 in patients with Q fever
fatigue syndrome (QFS) and
asymptomatic Q fever
seropositive controls, together
with production of CXCL9,
CXCL10, and CXCL11 in QFS
patients
QFS-recovered
(n = 8)
QFS-persistent
complaints (n = 27)
Q fever seropositive
controls (n = 10)
IFNγ production, pg/mL (IQR) 107 (69–271) 288 (98–574) 267 (100–395)
Nil, pg/mL (IQR) 5 (2–7) 5 (3–7) 4 (3–12)
IL-2 production, pg/mL (IQR) 114 (40–253) 147 (66–614) 289 (127–543)
Nil, pg/mL (IQR) 0 (0–1) 0 (0–0) 68 (5–117)
Ratio IFNγ/IL-2 (IQR) 1 (1–3) 1 (1–2) 1 (1–2)
CXCL9 production, pg/mL (IQR) 436 (378) 803 (558–1572) –
Nil, pg/mL (IQR) 217 (141–718) 171 (131–292) –
CXCL10 production, pg/mL (IQR) 97 (66–156) 176 (112–267) –
Nil, pg/mL (IQR) 57 (47–69) 63 (37–102) –
CXCL11 production, pg/mL (IQR) 19 (14–24) 18 (14–22) –
Nil, pg/mL (IQR) 12 (10–22) 9 (7–12) –
Median IFNγ, IL-2, CXCL9, CXCL10, and CXCL11 production and IFNγ/IL-2 ratio after 24-h incubation of
whole blood with C. burnetii 2009–02629 or RPMI (Nil)
IFNγ interferon-gamma, IL interleukin, CXCL C-X-C ligand, QFS Q fever fatigue syndrome, IQR interquartile
range, Nil negative control, i.e., Roswell Park Memorial Institute medium
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surpassing asymptomatic Q fever seropositive controls. Even
though a non-significant difference is seen, it was expected that
antigen-specific IL-2 production and IFNγ/IL-2 ratio would not
be able to discriminate between QFS patients with persisting
complaints, QFS patients who recovered from their complaints,
and asymptomatic Q fever seropositive controls [8].
An interesting difference between the present cohort of
asymptomatic Q fever seropositive controls and the cohort
that was published by Keijmel et al. [8] is that the present
cohort reported a symptomatic acute Q fever infection during
the outbreak, while the group of Keijmel et al. was found
seropositive by screening and hence contained a large number
of individuals who did not experience a symptomatic acute Q
fever infection. Keeping in mind that high IFNγ, and low IL-
10, production phenotypes have been associated with a more
severe and long-lasting acute illness, it is conceivable that the
individuals of the cohort of Keijmel et al. have a lower IFNγ
response in the long term, compared to those who experienced
a symptomatic acute Q fever infection [18]. It should also be
noted that the present cohort of asymptomatic Q fever sero-
positive controls was recruited from Herpen, a small town in
the Netherlands where the outbreak hit hardest. Therefore,
although IFNγ responses appear similar between patients with
persistent complaints and asymptomatic Q fever seropositive
controls in our study, there are several factors that are likely to
influence this observation. In order to better understand the
kinetics of antigen-specific IFNγ production in QFS patients
and asymptomatic Q fever seropositive controls, we suggest
Fig. 1 IFNγ, IL-2, CXCL9, CXCL10, and CXCL11 production in Q
fever fatigue syndrome (QFS) patients and asymptomatic Q fever
seropositive controls. a C.b. 2009-02629-induced net IFNγ production
after 24 h incubation of whole blood, showing no significant difference in
IFNγ production between QFS patients with persisting complaints, QFS
patients who recovered from their complaints, and asymptomatic Q fever
seropositive controls. b C.b. 2009-02629-induced net IL-2 production
after 24 h incubation of whole blood, showing no significant difference
in IL-2 production between QFS patients with persisting complaints, QFS
patients who recovered from their complaints, and asymptomatic Q fever
seropositive controls. c IFNγ/IL-2 ratio, showing no significant differ-
ence between QFS patients with persisting complaints, QFS patients who
recovered from their complaints, and asymptomatic Q fever seropositive
controls. d C.b. 2009-02629-induced net CXCL9 production after 24 h
incubation of whole blood, showing no significant difference in CXCL9
production between QFS patients with persisting complaints and QFS
patients who recovered from their complaints. e C.b. 2009-02629-
induced net CXCL10 production after 24 h incubation of whole blood,
showing no significant difference in CXCL10 production between QFS
patients with persisting complaints and QFS patients who recovered from
their complaints. f C.b. 2009-02629-induced net CXCL11 production
after 24 h incubation of whole blood, showing no significant difference
in CXCL11 production between QFS patients with persisting complaints
and QFS patients who recovered from their complaints. Median ± IQR
are shown. The Mann-Whitney and Kruskall-Wallis test were used.
Figure was made in Gaphpad Prism. Abbreviations: IFNγ = interferon-
gamma; IL = interleukin; CXCL = C-X-C ligand; QFS =Q fever fatigue
syndrome; C.b. =Coxiella burnetii; Recovered QFS =QFS patients who
recovered from their complaints; Persistent QFS = QFS patients with
persisting complaints; No QFS = asymptomatic Q fever seropositive
controls; IQR = interquartile range
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measuring IFNγ production longitudinally, starting at the time
of infection. Unfortunately, given the current low incidence
rates of acute Q fever infections [RIVM–Q fever], such a study
is hard to conduct in the Netherlands. As we did not measure
longitudinally, we do not know whether the slope of immune
reactivity differs between patients who become asymptomatic
following their symptomatic acute Q fever infection and those
who protract persistent complaints. It is of interest though that
we do see somewhat higher IL-2 responses and a lower IFNγ/
IL-2 ratio in the asymptomatic Q fever seropositive control
group of our study. This is an argument indeed that patients
with persistent complaints might differ from those who recover
from their acute Q fever infection.
A recent study showed that antigen-specific production of
CXCL9 and CXCL11, but not CXCL10, could further help
differentiate chronic Q fever patients from Q fever seropositive
controls [9]. Our results show that QFS patients who recovered
from their complaints have less antigen-specific CXCL10 pro-
duction than those with persistent complaints. This was to a
lesser extent also the case for CXCL9, but not for CXCL11.
Unfortunately, we were unable to test antigen-specific CXCL9,
CXCL10, and CXCL11 production in asymptomatic Q fever
seropositive controls. Nonetheless, as is the case for IFNγ,
these results do point towards an altered cell-mediated immu-
nity in between QFS patients with persisting complaints and
those who recovered from their complaints and show potential
for antigen-specific CXCL10 production to serve as a bio-
marker for perceived complaints in QFS.
An interesting question that remains is whether recovering
from QFS results in a tempered antigen-specific immune re-
sponse, or complaints persist because of a perpetuating immu-
nologic etiology. The pathophysiology of QFS remains un-
clear and theories range from chronic immune stimulation to
perpetuating compensation-driven and psychogenic factors
[19]. It has long been postulated that the etiology of chronic
fatigue syndromes might very well be multi-factorial and
could differ per patient. If this is the case for QFS, antigen-
specific IFNγ and CXCL10 production might help clinicians
differentiate in underlying etiology and subsequently better
specify therapeutic decision making, i.e., shifting focus to-
wards a more somatic or psychological perpetuation of com-
plaints, for cognitive behavioral therapists [10].
Although this study points towards an altered cell-
medicated immunity in QFS patients with persistent com-
plaints compared to those who recovered from their com-
plaints and shows possible roles for antigen-specific IFNγ
and CXCL10 to serve as biomarkers for perceived complaints
in QFS, there are several limitations. One limitation is the
small group size of QFS patients who recovered from their
complaints and missing CXCL9, CXCL10, and CXCL11 data
for asymptomatic Q fever seropositive controls. For studies
like this, in which sensitive biomarkers are tested in difficult-
to-define patient populations, it is paramount to have adequate
and ample control groups. Unfortunately, we were unable to
draft more QFS patients who recovered from their complaints
and asymptomatic Q fever seropositive controls. Additionally,
due to an interassay coefficient of variability well above 15%,
we had to exclude data for antigen-specific CXCL9,
CXCL10, and CXCL11 production in asymptomatic Q fever
seropositive controls. As the negative control samples of the
asymptomatic Q fever seropositive controls were unusually
high, we decided this run to be faulty and proceeded with
excluding these data from our manuscript. However, even
with these limitations, the results of this study give us addi-
tional insight in the underlying cell-mediated immunity of
perceived complaints in QFS. It also exposes an interesting
potential for antigen-specific biomarkers, e.g., IFNγ and
CXCL, to help clinicians more objectively diagnose QFS.
Conclusion
QFS patients with persisting complaints might exhibit a dif-
ferent cell-mediated immunity compared to those who recov-
ered from their complaints. Furthermore, antigen-specific
IFNγ and CXCL10 production could serve as potential bio-
markers for perceived complaints in QFS and possibly also as
indicators of underlying etiology. We recommend further in-
vestigation into the role of these biomarkers in the pathophys-
iology of and diagnostic use for QFS patients with adequately
sized control groups.
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